Karyopharm Therapeutics (KPTI) Competitors

$1.88 +0.09 (+5.03%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.77 -0.11 (-5.90%)

As of 09/18/2026 07:51 PM Eastern

KPTI vs. UNCY, LENZ, VTVT, MIST, and RFL

Should you buy Karyopharm Therapeutics stock or one of its competitors? Karyopharm Therapeutics's main competitors and comparable companies include Unicycive Therapeutics (UNCY), LENZ Therapeutics (LENZ), vTv Therapeutics (VTVT), Milestone Pharmaceuticals (MIST), and Rafael (RFL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Karyopharm Therapeutics compare to Unicycive Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Unicycive Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	0.29	-$196.04M	-$13.09	N/A
Unicycive Therapeutics	$680K	196.59	-$26.56M	-$1.75	N/A

Karyopharm Therapeutics presently has a consensus target price of $11.50, suggesting a potential upside of 511.70%. Unicycive Therapeutics has a consensus target price of $18.75, suggesting a potential upside of 290.63%. Given Karyopharm Therapeutics' higher probable upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Unicycive Therapeutics had 17 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 17 mentions for Unicycive Therapeutics and 0 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.00 beat Unicycive Therapeutics' score of -0.01 indicating that Karyopharm Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Karyopharm Therapeutics	Neutral
Unicycive Therapeutics	Neutral

Karyopharm Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market.

Unicycive Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%. Karyopharm Therapeutics' return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-153.28%	N/A	-145.18%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

Summary

Unicycive Therapeutics beats Karyopharm Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to LENZ Therapeutics?

Karyopharm Therapeutics (NASDAQ:KPTI) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Karyopharm Therapeutics has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the broader market.

LENZ Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	0.29	-$196.04M	-$13.09	N/A
LENZ Therapeutics	$19.09M	6.70	-$82.13M	-$4.09	N/A

In the previous week, LENZ Therapeutics had 3 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 3 mentions for LENZ Therapeutics and 0 mentions for Karyopharm Therapeutics. LENZ Therapeutics' average media sentiment score of 0.16 beat Karyopharm Therapeutics' score of 0.00 indicating that LENZ Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Karyopharm Therapeutics	Neutral
LENZ Therapeutics	Neutral

Karyopharm Therapeutics has a net margin of -153.28% compared to LENZ Therapeutics' net margin of -586.74%. Karyopharm Therapeutics' return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-153.28%	N/A	-145.18%
LENZ Therapeutics	-586.74%	-53.39%	-49.14%

Karyopharm Therapeutics currently has a consensus price target of $11.50, suggesting a potential upside of 511.70%. LENZ Therapeutics has a consensus price target of $28.80, suggesting a potential upside of 607.62%. Given LENZ Therapeutics' higher probable upside, analysts plainly believe LENZ Therapeutics is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

LENZ Therapeutics beats Karyopharm Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

vTv Therapeutics has higher earnings, but lower revenue than Karyopharm Therapeutics. vTv Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	122.84	-$26.97M	-$1.06	N/A
Karyopharm Therapeutics	$146.07M	0.29	-$196.04M	-$13.09	N/A

vTv Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%. Karyopharm Therapeutics' return on equity of 0.00% beat vTv Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-6.27%	-5.06%
Karyopharm Therapeutics	-153.28%	N/A	-145.18%

vTv Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

vTv Therapeutics presently has a consensus target price of $55.83, indicating a potential upside of 75.58%. Karyopharm Therapeutics has a consensus target price of $11.50, indicating a potential upside of 511.70%. Given Karyopharm Therapeutics' higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

In the previous week, vTv Therapeutics had 2 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 2 mentions for vTv Therapeutics and 0 mentions for Karyopharm Therapeutics. vTv Therapeutics' average media sentiment score of 0.37 beat Karyopharm Therapeutics' score of 0.00 indicating that vTv Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
vTv Therapeutics	Neutral
Karyopharm Therapeutics	Neutral

Summary

vTv Therapeutics beats Karyopharm Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Milestone Pharmaceuticals?

Karyopharm Therapeutics (NASDAQ:KPTI) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by company insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Karyopharm Therapeutics' average media sentiment score of 0.00 equaled Milestone Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Karyopharm Therapeutics	Neutral
Milestone Pharmaceuticals	Neutral

Karyopharm Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

Milestone Pharmaceuticals has lower revenue, but higher earnings than Karyopharm Therapeutics. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	0.29	-$196.04M	-$13.09	N/A
Milestone Pharmaceuticals	$1.55M	73.56	-$63.06M	-$0.69	N/A

Karyopharm Therapeutics currently has a consensus price target of $11.50, suggesting a potential upside of 511.70%. Milestone Pharmaceuticals has a consensus price target of $6.40, suggesting a potential upside of 598.84%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Milestone Pharmaceuticals has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%. Karyopharm Therapeutics' return on equity of 0.00% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-153.28%	N/A	-145.18%
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%

Summary

Milestone Pharmaceuticals beats Karyopharm Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Rafael?

Karyopharm Therapeutics (NASDAQ:KPTI) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

In the previous week, Rafael had 1 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 1 mentions for Rafael and 0 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.00 equaled Rafael'saverage media sentiment score.

Company	Overall Sentiment
Karyopharm Therapeutics	Neutral
Rafael	Neutral

Rafael has lower revenue, but higher earnings than Karyopharm Therapeutics. Rafael is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07M	0.29	-$196.04M	-$13.09	N/A
Rafael	$920K	116.27	-$30.52M	-$0.68	N/A

Karyopharm Therapeutics presently has a consensus target price of $11.50, suggesting a potential upside of 511.70%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Karyopharm Therapeutics is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

66.4% of Karyopharm Therapeutics shares are held by institutional investors. Comparatively, 11.3% of Rafael shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by insiders. Comparatively, 32.9% of Rafael shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Karyopharm Therapeutics has a net margin of -153.28% compared to Rafael's net margin of -3,321.74%. Karyopharm Therapeutics' return on equity of 0.00% beat Rafael's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-153.28%	N/A	-145.18%
Rafael	-3,321.74%	-41.27%	-35.32%

Karyopharm Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, Rafael has a beta of 0.4, suggesting that its share price is 60% less volatile than the broader market.

Summary

Karyopharm Therapeutics beats Rafael on 10 of the 16 factors compared between the two stocks.

Get Karyopharm Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KPTI vs. The Competition

Export

Metric	Karyopharm Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$42.64M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	-0.14	797.25	275.49	25.40
Price / Sales	0.29	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	-0.12	10.53	10.46	6.33
Net Income	-$196.04M	$2.82B	$3.49B	$358.33M
7 Day Performance	16.77%	1.69%	0.59%	1.12%
1 Month Performance	3.30%	0.24%	-1.74%	-2.39%
1 Year Performance	-65.25%	3.95%	18.13%	5.35%

Karyopharm Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KPTI Karyopharm Therapeutics	2.3538 of 5 stars	$1.88 +5.0%	$11.50 +511.7%	-65.2%	$42.64M	$146.07M	N/A	228
UNCY Unicycive Therapeutics	3.0792 of 5 stars	$5.15 -2.6%	$18.75 +264.1%	+21.2%	$143.45M	N/A	N/A	9
LENZ LENZ Therapeutics	2.7282 of 5 stars	$4.47 -1.1%	$28.80 +544.3%	-90.4%	$140.45M	$21.48M	N/A	110	News Coverage
VTVT vTv Therapeutics	3.0883 of 5 stars	$31.44 -1.7%	$55.83 +77.6%	+42.1%	$125.93M	$1.02M	N/A	9	Positive News
MIST Milestone Pharmaceuticals	1.8054 of 5 stars	$0.95 -3.1%	$6.40 +574.1%	-52.3%	$122.02M	$2.34M	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KPTI) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Karyopharm Therapeutics (KPTI) Competitors

KPTI vs. UNCY, LENZ, VTVT, MIST, and RFL

How does Karyopharm Therapeutics compare to Unicycive Therapeutics?

Summary

How does Karyopharm Therapeutics compare to LENZ Therapeutics?

Summary

How does Karyopharm Therapeutics compare to vTv Therapeutics?

Summary

How does Karyopharm Therapeutics compare to Milestone Pharmaceuticals?

Summary

How does Karyopharm Therapeutics compare to Rafael?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI vs. The Competition

Karyopharm Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Karyopharm Therapeutics (KPTI) Competitors

KPTI vs. UNCY, LENZ, VTVT, MIST, and RFL

How does Karyopharm Therapeutics compare to Unicycive Therapeutics?

Which has preferable valuation and earnings, KPTI or UNCY?

Do analysts prefer KPTI or UNCY?

Do institutionals & insiders hold more shares of KPTI or UNCY?

Does the media favor KPTI or UNCY?

Which has more volatility & risk, KPTI or UNCY?

Is KPTI or UNCY more profitable?

Summary

How does Karyopharm Therapeutics compare to LENZ Therapeutics?

Do insiders & institutionals hold more shares of KPTI or LENZ?

Which has more risk & volatility, KPTI or LENZ?

Which has preferable earnings and valuation, KPTI or LENZ?

Does the media prefer KPTI or LENZ?

Is KPTI or LENZ more profitable?

Do analysts recommend KPTI or LENZ?

Summary

How does Karyopharm Therapeutics compare to vTv Therapeutics?

Which has higher valuation and earnings, VTVT or KPTI?

Is VTVT or KPTI more profitable?

Which has more risk & volatility, VTVT or KPTI?

Do insiders & institutionals believe in VTVT or KPTI?

Do analysts recommend VTVT or KPTI?

Does the media favor VTVT or KPTI?

Summary

How does Karyopharm Therapeutics compare to Milestone Pharmaceuticals?

Do institutionals and insiders have more ownership in KPTI or MIST?

Does the media prefer KPTI or MIST?

Which has more risk & volatility, KPTI or MIST?

Which has preferable valuation and earnings, KPTI or MIST?

Do analysts recommend KPTI or MIST?

Is KPTI or MIST more profitable?

Summary

How does Karyopharm Therapeutics compare to Rafael?

Does the media prefer KPTI or RFL?

Which has stronger earnings & valuation, KPTI or RFL?

Do analysts prefer KPTI or RFL?

Do insiders and institutionals have more ownership in KPTI or RFL?

Is KPTI or RFL more profitable?

Which has more volatility & risk, KPTI or RFL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI vs. The Competition

Karyopharm Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools